Agilent Technologies (A) recently announced an expansion of its Altura HPLC column portfolio and introduced AI-powered xCELLigence RTCA eSight software, product updates that have drawn fresh attention to how the stock reflects its life sciences focus.

Agilent Technologies' recent product releases have arrived alongside a gradual improvement in sentiment. The stock has delivered a 14.29% 90 day share price return, while the 1 year total shareholder return of 9.80% contrasts with a share price that is still down 2.65% year to date. This indicates that momentum has been rebuilding after earlier weakness.

If you are interested in how tools like AI powered lab software could influence other opportunities across the sector, it may be worth checking out 41 healthcare AI stocks

For Agilent Technologies, recent gains could either reflect growing confidence in its life sciences engine or a short term mood shift after earlier weakness. To judge which interpretation fits, the valuation picture comes next.

Most Popular Narrative: 16.6% Undervalued

Agilent Technologies' most followed valuation narrative places fair value at $161, compared with the latest close of $134.29. This frames the recent rebound against expectations for steadier growth and profitability.

Strategic investments in higher margin recurring revenue streams including consumables, software, services, and digital platforms are gaining traction, with CrossLab and services delivering consistent mid single digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.

Want to see what is baked into that $161 fair value for Agilent Technologies? The narrative leans heavily on recurring revenues, rising margins, and a richer earnings mix. Curious which assumptions around growth, profitability, and required return actually carry the model?

Result: Fair Value of $161 (UNDERVALUED)

However, the Agilent Technologies narrative still faces pressure from rising tariff related costs and the risk that weaker research funding could limit demand in key end markets.

Another View: What Agilent Technologies' P/E Ratio Is Telling You

The DCF workup points to Agilent Technologies trading below estimated future cash flow value, but the P/E picture is less one sided. The stock trades on 26.8x earnings, higher than its fair ratio of 23.6x, yet lower than the 37.7x industry average and 42.7x peer average. Is that a valuation cushion or a warning sign if sentiment cools?

For a closer look at what this earnings multiple gap could mean in practice, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and caution around Agilent Technologies so far feels balanced, now is a good time to review the details yourself and decide how convincing the story really is based on your own criteria. To see what other investors view as the main positives, take a closer look at the 3 key rewards

Looking for more investment ideas beyond Agilent Technologies?

If Agilent Technologies has you thinking more broadly about opportunities, now is the moment to scan other stocks and avoid missing ideas that fit your style.

• Target companies that trade below what their fundamentals suggest by reviewing the 45 high quality undervalued stocks and see which ones match your return expectations.
• Strengthen your income stream by checking out the 9 dividend fortresses and focus on companies offering higher yields with supporting fundamentals.
• Prioritize stability by using the 78 resilient stocks with low risk scores to spot companies with resilience that may better suit a cautious approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.